-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13

Benzinga·06/24/2026 18:50:15
Listen to the news
Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Overweight rating and announces Price Target of $13.